The European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) released key policy decisions following its plenary session. The primary focus centered on administrative and regulatory modernizations to streamline authorizations for novel animal health therapeutics.
Institutional Impact: “One Substance, One Assessment”
Under the broader European Green Deal and Chemical Strategy for Sustainability, the CVMP’s policy alignment establishes a consolidated safety assessment pipeline:
-
Elimination of Duplicate Data Requirements: Toxicological assessments and Maximum Residue Limits (MRLs) for compounds used in both agriculture and veterinary medicine will rely on shared cross-agency data repositories.
-
Accelerated Timelines for Novel Therapeutics: By standardizing environmental risk assessments (ERAs), biotech applicants targeting target-animal safety profiles face fewer redundant procedural delays.
Key Product Opinions & Approvals
Alongside policy updates, the CVMP granted positive opinions for several veterinary medicinal products (VMPs):
-
Swine & Poultry Immunologics: Adoption of positive opinions for novel vaccines addressing Porcine Circovirus Type 2 (PCV2) and Salmonella Typhimurium in poultry flocks.
-
Indication Expansions: Approval of label variations for companion animal parasiticides (Felpreva, Vectra 3D) to expand therapeutic indications against tick-borne pathogens and Leishmania infantum vectors.
